We are fully equipped and well-positioned to realize the potential of Encoded’s novel approach to gene therapy for people living with pediatric central nervous system (CNS) diseases and their families.
Creating a Viable and Sustainable Gene Therapy Innovation Engine
Our team brings to Encoded the right mix of innovation and expertise across all aspects of gene therapy development.
From whiteboard to lab and from lab to clinic, our team knows how to take a gene therapy from concept to commercial. The depth and breadth of our team’s expertise in developing and bringing to market gene therapies are second to none.
Board of Directors
Our board members have proven track records building life science companies and developing and commercializing cell and gene therapies, many of them being forebears and early innovators in this space.
Our mission is to develop transformative therapies by fostering a culture of relentless patient focus, creativity and scientific exploration.
Our C.O.D.E. for Success
Hope is encoded in our DNA, and our values are at the heart of everything we do.
Our Commitment to Diversity
Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. Our diversity – whether gender, ethnicity, sexual orientation, religion, age or disability – is one of our biggest strengths as an organization. We welcome differences in opinion as an opportunity to broaden our understanding, and we are decidedly collaborative, recognizing the importance of connectivity and the unique contributions of each individual.
Our company and leadership have been recently recognized for our know-how, innovative spirit and technology. Check out some of our awards.
We are evaluating opportunities for collaboration where we can utilize our research platform, which focuses on increased selectivity and potency through improved expression profiles. We believe this approach can be enabling for best- and/or first-in-class gene therapies across a broad range of indications in the CNS and other organ systems. To date, we have completed proof-of-concept work in CNS, liver, heart and metabolic areas. Currently, we are not actively seeking to license any of our CNS pipeline assets. For more information on partnering, please email us at firstname.lastname@example.org.